Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders.
Alzheimer’s disease
amotivation
apathy
neurodegenerative disorders
pharmacology
treatment
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
08
2019
accepted:
05
12
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.
Identifiants
pubmed: 32038253
doi: 10.3389/fphar.2019.01581
pmc: PMC6989486
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1581Informations de copyright
Copyright © 2020 Bogdan, Manera, Koenig and David.
Références
PLoS One. 2017 Mar 21;12(3):e0173872
pubmed: 28323838
CNS Spectr. 2018 Dec;23(6):361-369
pubmed: 28911339
Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-1928
pubmed: 28790827
Psychogeriatrics. 2017 May;17(3):186-193
pubmed: 28130887
Parkinsonism Relat Disord. 2019 Mar;60:14-24
pubmed: 30470658
Am J Geriatr Psychiatry. 2011 Jul;19(7):644-53
pubmed: 21709610
Exp Ther Med. 2019 Mar;17(3):1625-1630
pubmed: 30783429
Drugs R D. 2019 Jun;19(2):93-115
pubmed: 31098864
Nat Rev Neurosci. 2018 Aug;19(8):470-484
pubmed: 29946157
Cochrane Database Syst Rev. 2018 May 04;5:CD012197
pubmed: 29727467
J Alzheimers Dis. 2015;48(2):377-83
pubmed: 26402001
Rev Neurol (Paris). 2018 Apr;174(4):182-189
pubmed: 29606317
Am J Geriatr Psychiatry. 2019 Apr;27(4):395-405
pubmed: 30655032
Ther Adv Psychopharmacol. 2018 Jan;8(1):33-48
pubmed: 29344342
Am J Geriatr Psychiatry. 2013 Nov;21(11):1098-106
pubmed: 23636003
J Parkinsons Dis. 2018;8(3):409-420
pubmed: 30056433
Mov Disord. 2019 Nov;34(11):1644-1654
pubmed: 31309609
J Pineal Res. 2018 Nov;65(4):e12515
pubmed: 29907977
Lancet Neurol. 2018 Mar;17(3):223-231
pubmed: 29452685
J Neurol Sci. 2017 Jan 15;372:279-287
pubmed: 28017228
Can J Neurol Sci. 2017 May;44(3):267-275
pubmed: 28148339
J Neurol Sci. 2011 Nov 15;310(1-2):58-60
pubmed: 21831400
Funct Neurol. 2018 Oct/Dec;33(4):213-216
pubmed: 30663968
Intern Med. 2019 Feb 1;58(3):361-368
pubmed: 30146591
J Stroke Cerebrovasc Dis. 2016 May;25(5):1119-1127
pubmed: 26915605
Am J Geriatr Psychiatry. 2007 May;15(5):386-94
pubmed: 17463189
Drugs. 2017 Sep;77(13):1423-1459
pubmed: 28776162
Parkinsonism Relat Disord. 2019 Feb;59:65-73
pubmed: 30852149
Mov Disord. 2019 Feb;34(2):180-198
pubmed: 30653247
Int Rev Neurobiol. 2017;134:1019-1044
pubmed: 28805563
Front Psychol. 2019 Jan 23;9:2781
pubmed: 30728798
Clin Neurol Neurosurg. 2008 Jan;110(1):19-24
pubmed: 17900799
J Neurol Sci. 2019 Jan 15;396:78-83
pubmed: 30423541
J Alzheimers Dis. 2017;56(2):805-815
pubmed: 28035924
J Geriatr Psychiatry Neurol. 2019 May;32(3):164-169
pubmed: 30913958
J Neuropsychiatry Clin Neurosci. 2009 Summer;21(3):259-65
pubmed: 19776304
Brain Stimul. 2014 Mar-Apr;7(2):308-13
pubmed: 24262299
Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):233-240
pubmed: 27998194
J Neurol Sci. 2018 Oct 15;393:31-38
pubmed: 30099246
Alzheimers Dement. 2017 Jan;13(1):84-100
pubmed: 27362291
J Alzheimers Dis Rep. 2017 Dec 9;1(1):229-235
pubmed: 30480240
Am J Geriatr Psychiatry. 2013 Sep;21(9):840-7
pubmed: 23567364
CNS Drugs. 2018 Jul;32(7):621-635
pubmed: 30027401
J Geriatr Psychiatry Neurol. 2017 Jan;30(1):26-49
pubmed: 28248559
Prog Neurobiol. 2009 Jun;88(2):127-51
pubmed: 19482229
Alzheimers Res Ther. 2018 Sep 27;10(1):102
pubmed: 30261917
Trials. 2018 Jan 18;19(1):46
pubmed: 29347996
J Neurosci. 2018 Feb 28;38(9):2149-2162
pubmed: 29367407
J Clin Psychiatry. 2013 Aug;74(8):810-6
pubmed: 24021498
Neuropsychopharmacology. 2019 May;44(6):1068-1075
pubmed: 30478410
Parkinsons Dis. 2017;2017:6219851
pubmed: 28409049